论文部分内容阅读
本刊讯加拿大卫生部进行了一项安全性审查,以考察Avonex(干扰素β-1a)使用时出现血栓性微血管病的潜在风险。此风险信号是在审查药品生产商提供的新安全性信息时发现的。Avonex(干扰素β-1a)适用于治疗某些形式的多发性硬化症,以减少中枢神经系统的损伤,并延缓疾病的恶化。Avonex通过肌内注射给药,单次剂量为30 mg,每周1次。该药于2005年12月在加拿大上市销售,仅可凭处方购买。
Health Canada conducted a safety review to examine the potential risk of developing thrombotic microangiopathy when using Avonex (interferon beta-1a). This risk signal was discovered when reviewing new safety information provided by drug manufacturers. Avonex (interferon beta-1a) is suitable for the treatment of some forms of multiple sclerosis to reduce central nervous system damage and delay the progression of the disease. Avonex is administered by intramuscular injection at a single dose of 30 mg once weekly. The drug was marketed in Canada in December 2005 and can only be purchased on prescription.